TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...

TOKYO, Sept 26, 2022 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced today that they have obtained ...

Methotrexate The effectiveness of oral vs subcutaneous methotrexate for the treatment of psoriasis in a registry is reported. More patients with psoriasis who were treated with subcutaneous ...

Many people living with rheumatoid arthritis (RA) rely on long-term medications to manage joint pain, stiffness, and inflammation. A number of these treatments are given as subcutaneous injections, ...

Subcutaneous tocilizumab, alone or with methotrexate, showed superior efficacy over methotrexate monotherapy in treating rheumatoid arthritis in Chinese patients. The trial demonstrated higher ACR20 ...

Please provide your email address to receive an email when new articles are posted on . Subcutaneous methotrexate is safe in clinical practice, and is continued longer and better tolerated than other ...

Methotrexate is a prescription medication. It comes in four forms: self-injectable solution, injectable IV solution, oral tablet, and oral solution. For the self-injectable solution, you can receive ...

Methotrexate is a generic drug prescribed to treat certain types of cancers, arthritis, and psoriasis in adults and some children. As with other drugs, methotrexate can cause side effects, such as ...

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

Methotrexate injection, a treatment for certain autoimmune diseases and cancers, can lead to various side effects. These range from common, mild reactions such as headache and nausea to serious, ...

Please provide your email address to receive an email when new articles are posted on . Olokizumab demonstrated superiority compared with placebo and non-inferiority compared with adalimumab in ...